Treatment with pioglitazone (Actos) was able to halt the progression of impaired glucose tolerance to type 2 diabetes in a majority of patients, a randomized trial found.
After a mean follow-up of 2.2 years, 5% of patients with impaired glucose tolerance treated with Actos had developed diabetes, compared with 16.7% of those on placebo, according to Ralph A. DeFronzo, MD, of the University of Texas in San Antonio, as reported in the March 24 New England Journal of Medicine.
For more information please visit the original diabetes network at http://www.diabetes.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment